ArticleEuropean journal of clinical pharmacology2010
A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system.
Article in European journal of clinical pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pooled it
- Abuse and Misuse of Pregabalin and Gabapentin.Drugs · 2017Pooled it
- Abuse Potential of Pregabalin: A Systematic Review.CNS drugs · 2016Pooled it
- Pharmacotherapy for anxiety and comorbid alcohol use disorders.The Cochrane database of systematic reviews · 2015Pooled it
- Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers.Psychopharmacology · 2012Trial
- Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers.Pharmacology, biochemistry, and behavior · 2012Trial
- Patterns of pregabalin misuse: Need for intervention.The Indian journal of medical research · 2026Article
- A hospital-based multi-centric observational study to explore the prevalence and correlates of non-medical use and dependence of pregabalin among the patients with substance use disorder in Punjab & Chandigarh.Substance abuse treatment, prevention, and policy · 2026Observational
- Trends in pregabalin misuse and abuse: A 25-year bibliometric perspective.Journal of medical biochemistry · 2026Article
- Monitoring pregabalin use through online interest: A trend analysis using google search and consumption data.Indian journal of psychiatry · 2025Article
- Seizures as an Adverse Effect of Pregabalin Consumption: A Systematic Review.Addiction & health · 2025Review
- A case report of pregabalin misuse leading to drug dependence.Frontiers in psychiatry · 2025Article
- Characteristics of Non-Therapeutic Pregabalin Users Detected by a Community Pharmacies Network in a Region of Southern Europe.Journal of clinical medicine · 2024Article
- Chronic pregabalin treatment reduced anxiety, and acute pregabalin treatment increased depression-like behaviors in rats.BMC pharmacology & toxicology · 2024Article
- Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022.CNS drugs · 2024Article
- Understanding pregabalin misuse and dependence: Insights from a North Indian addiction treatment center.Indian journal of psychiatry · 2024Article
- Pregabalin dependence - A rising concern.Industrial psychiatry journal · 2024Article
- Trends in the prescription of opioids and gabapentinoids in patients with failed back surgery syndrome in Korea: a population-based study.The Korean journal of pain · 2024Article
- Article
- Chinese-Named Entity Recognition From Adverse Drug Event Records: Radical Embedding-Combined Dynamic Embedding-Based BERT in a Bidirectional Long Short-term Conditional Random Field (Bi-LSTM-CRF) Model.JMIR medical informatics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePregabalin is a gamma-aminobutyric acid (GABA) analogue approved for the treatment of epilepsy, neuropathic pain and generalised anxiety disorder. As a GABA analogue, there has been some concern about an abuse liability. We aimed to investigate the possible abuse liability of pregabalin.
methodsBy applying a Bayesian data-mining algorithm to reports of possible drug abuse or addiction in the Swedish national register of adverse drug reactions (SWEDIS), we calculated the information component (IC) for pregabalin and reports of abuse and addiction.
resultsOut of 198 reports indicative of abuse or addiction to any drug, 16 concerned pregabalin. The IC became significantly elevated in the fourth quarter of 2008, rising to 3.99 (95% confidence interval 3.21-4.59) at the end of 2009.
conclusionBased on the signal from the present study, we conclude that pregabalin is likely to be associated with an abuse potential.
Indexed as
Identifiers
20563568What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.